The burden of migraine in the United States: Current and emerging perspectives on disease management and economic analysis

Elisabeth Hazard, Julie Munakata, Marcelo E. Bigal, Marcia F T Rupnow, Richard B. Lipton

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Objectives: Migraine is often perceived as a low-impact condition that imposes a limited burden to society and the health-care system. This study reviews the current understanding of the burden of migraine in the U.S., the history of economic understanding of migraine treatment and identifies emergent trends for future studies evaluating clinical and economic outcomes of migraine treatment. Methods: This study traced the history of economic articles published on migraine by performing a literature search using PubMed MEDLINE database and ancestral searches of relevant articles. The intention was not to provide an exhaustive review of every article or adjudicate between studies with different findings. Results: Migraine affects millions of individuals worldwide, generally during the most productive years of a person's life. Studies show that migraineurs are underdiagnosed, undertreated, and experience substantial decreases in functioning and productivity, which in turn translates into diminished quality of life for individuals, and financial burdens to both health-care systems and employers. Economic evaluations of migraine therapies have evolved with new clinical developments beginning with cognitive-behavioral therapy, introduction of triptans, concern over medication overuse, and emergence of migraine prophylaxis. Now recent clinical studies suggest that migraine may be a progressive disease with cardiovascular, cerebrovascular, and long-term neurologic effects. Conclusions: Migraine imposes a substantial burden on patients, families, employers and societies. The economic standards by which migraine and treatment are evaluated have evolved in response to clinical developments. Emerging evidence suggests that migraine is a chronic and progressive disease. If confirmed, approaches to acute and prophylactic treatments and economic evaluations of migraine treatment may require major reconsideration.

Original languageEnglish (US)
Pages (from-to)55-64
Number of pages10
JournalValue in Health
Volume12
Issue number1
DOIs
StatePublished - Jan 2009

Fingerprint

Disease Management
Migraine Disorders
Economics
Cost-Benefit Analysis
History
Tryptamines
Delivery of Health Care
Therapeutics
Cognitive Therapy
PubMed
MEDLINE
Nervous System
Chronic Disease
Cardiovascular Diseases
Quality of Life
Databases

Keywords

  • Burden of illness
  • Economic
  • Migraine
  • United States

ASJC Scopus subject areas

  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this

The burden of migraine in the United States : Current and emerging perspectives on disease management and economic analysis. / Hazard, Elisabeth; Munakata, Julie; Bigal, Marcelo E.; Rupnow, Marcia F T; Lipton, Richard B.

In: Value in Health, Vol. 12, No. 1, 01.2009, p. 55-64.

Research output: Contribution to journalArticle

Hazard, Elisabeth ; Munakata, Julie ; Bigal, Marcelo E. ; Rupnow, Marcia F T ; Lipton, Richard B. / The burden of migraine in the United States : Current and emerging perspectives on disease management and economic analysis. In: Value in Health. 2009 ; Vol. 12, No. 1. pp. 55-64.
@article{361d482f546543cfbd0375960ca4c402,
title = "The burden of migraine in the United States: Current and emerging perspectives on disease management and economic analysis",
abstract = "Objectives: Migraine is often perceived as a low-impact condition that imposes a limited burden to society and the health-care system. This study reviews the current understanding of the burden of migraine in the U.S., the history of economic understanding of migraine treatment and identifies emergent trends for future studies evaluating clinical and economic outcomes of migraine treatment. Methods: This study traced the history of economic articles published on migraine by performing a literature search using PubMed MEDLINE database and ancestral searches of relevant articles. The intention was not to provide an exhaustive review of every article or adjudicate between studies with different findings. Results: Migraine affects millions of individuals worldwide, generally during the most productive years of a person's life. Studies show that migraineurs are underdiagnosed, undertreated, and experience substantial decreases in functioning and productivity, which in turn translates into diminished quality of life for individuals, and financial burdens to both health-care systems and employers. Economic evaluations of migraine therapies have evolved with new clinical developments beginning with cognitive-behavioral therapy, introduction of triptans, concern over medication overuse, and emergence of migraine prophylaxis. Now recent clinical studies suggest that migraine may be a progressive disease with cardiovascular, cerebrovascular, and long-term neurologic effects. Conclusions: Migraine imposes a substantial burden on patients, families, employers and societies. The economic standards by which migraine and treatment are evaluated have evolved in response to clinical developments. Emerging evidence suggests that migraine is a chronic and progressive disease. If confirmed, approaches to acute and prophylactic treatments and economic evaluations of migraine treatment may require major reconsideration.",
keywords = "Burden of illness, Economic, Migraine, United States",
author = "Elisabeth Hazard and Julie Munakata and Bigal, {Marcelo E.} and Rupnow, {Marcia F T} and Lipton, {Richard B.}",
year = "2009",
month = "1",
doi = "10.1111/j.1524-4733.2008.00404.x",
language = "English (US)",
volume = "12",
pages = "55--64",
journal = "Value in Health",
issn = "1098-3015",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - The burden of migraine in the United States

T2 - Current and emerging perspectives on disease management and economic analysis

AU - Hazard, Elisabeth

AU - Munakata, Julie

AU - Bigal, Marcelo E.

AU - Rupnow, Marcia F T

AU - Lipton, Richard B.

PY - 2009/1

Y1 - 2009/1

N2 - Objectives: Migraine is often perceived as a low-impact condition that imposes a limited burden to society and the health-care system. This study reviews the current understanding of the burden of migraine in the U.S., the history of economic understanding of migraine treatment and identifies emergent trends for future studies evaluating clinical and economic outcomes of migraine treatment. Methods: This study traced the history of economic articles published on migraine by performing a literature search using PubMed MEDLINE database and ancestral searches of relevant articles. The intention was not to provide an exhaustive review of every article or adjudicate between studies with different findings. Results: Migraine affects millions of individuals worldwide, generally during the most productive years of a person's life. Studies show that migraineurs are underdiagnosed, undertreated, and experience substantial decreases in functioning and productivity, which in turn translates into diminished quality of life for individuals, and financial burdens to both health-care systems and employers. Economic evaluations of migraine therapies have evolved with new clinical developments beginning with cognitive-behavioral therapy, introduction of triptans, concern over medication overuse, and emergence of migraine prophylaxis. Now recent clinical studies suggest that migraine may be a progressive disease with cardiovascular, cerebrovascular, and long-term neurologic effects. Conclusions: Migraine imposes a substantial burden on patients, families, employers and societies. The economic standards by which migraine and treatment are evaluated have evolved in response to clinical developments. Emerging evidence suggests that migraine is a chronic and progressive disease. If confirmed, approaches to acute and prophylactic treatments and economic evaluations of migraine treatment may require major reconsideration.

AB - Objectives: Migraine is often perceived as a low-impact condition that imposes a limited burden to society and the health-care system. This study reviews the current understanding of the burden of migraine in the U.S., the history of economic understanding of migraine treatment and identifies emergent trends for future studies evaluating clinical and economic outcomes of migraine treatment. Methods: This study traced the history of economic articles published on migraine by performing a literature search using PubMed MEDLINE database and ancestral searches of relevant articles. The intention was not to provide an exhaustive review of every article or adjudicate between studies with different findings. Results: Migraine affects millions of individuals worldwide, generally during the most productive years of a person's life. Studies show that migraineurs are underdiagnosed, undertreated, and experience substantial decreases in functioning and productivity, which in turn translates into diminished quality of life for individuals, and financial burdens to both health-care systems and employers. Economic evaluations of migraine therapies have evolved with new clinical developments beginning with cognitive-behavioral therapy, introduction of triptans, concern over medication overuse, and emergence of migraine prophylaxis. Now recent clinical studies suggest that migraine may be a progressive disease with cardiovascular, cerebrovascular, and long-term neurologic effects. Conclusions: Migraine imposes a substantial burden on patients, families, employers and societies. The economic standards by which migraine and treatment are evaluated have evolved in response to clinical developments. Emerging evidence suggests that migraine is a chronic and progressive disease. If confirmed, approaches to acute and prophylactic treatments and economic evaluations of migraine treatment may require major reconsideration.

KW - Burden of illness

KW - Economic

KW - Migraine

KW - United States

UR - http://www.scopus.com/inward/record.url?scp=58849162823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58849162823&partnerID=8YFLogxK

U2 - 10.1111/j.1524-4733.2008.00404.x

DO - 10.1111/j.1524-4733.2008.00404.x

M3 - Article

C2 - 18671771

AN - SCOPUS:58849162823

VL - 12

SP - 55

EP - 64

JO - Value in Health

JF - Value in Health

SN - 1098-3015

IS - 1

ER -